Adipose-derived stem/stromal cells (ASCs) have been previously used for bone repair. However, significant cell heterogeneity exists within the ASC population, which has the potential to result in unreliable bone tissue formation and/or low efficacy. Although the use of cell sorting to lower cell heterogeneity is one method to improve bone formation, this is a technically sophisticated and costly process. In this study, we tried to find a simpler and more deployable solution—blocking antiosteogenic molecule Dickkopf-1 (DKK1) to improve osteogenic differentiation. Human adipose-derived stem cells were derived from = 5 samples of human lipoaspirate. In vitro, anti-DKK1 treatment, but not anti-sclerostin (SOST), promoted ASC osteogenic differentiation, assessed by alizarin red staining and real-time polymerase chain reaction (qPCR). Increased canonical Wnt signaling was confirmed after anti-DKK1 treatment. Expression levels of DKK1 peaked during early osteogenic differentiation (day 3). Concordantly, anti-DKK1 supplemented early (day 3 or before), but not later (day 7) during osteogenic differentiation positively regulated osteoblast formation. Finally, anti-DKK1 led to increased transcript abundance of the Wnt inhibitor SOST, potentially representing a compensatory cellular mechanism. In sum, DKK1 represents a targetable “molecular brake” on the osteogenic differentiation of human ASC. Moreover, release of this brake by neutralizing anti-DKK1 antibody treatment at least partially rescues the poor bone-forming efficacy of ASC.
Get full access to this article
View all access options for this article.
References
1.
LendeckelS, JödickeA, ChristophisP, HeidingerK, WolffJ, FraserJK, HedrickMH, BertholdL and HowaldtHP. (2004). Autologous stem cells (adipose) and fibrin glue used to treat widespread traumatic calvarial defects: case report. J Craniomaxillofac Surg, 32:370–373.
ZukP. (2013). Adipose-derived stem cells in tissue regeneration: a review. ISRN Stem Cells, 12:822.
4.
GrottkauBE and LinY. (2013). Osteogenesis of adipose-derived stem cells. Bone Res, 1:133–145.
5.
MüllerAM, MehrkensA, SchäferDJ, JaquieryC, GüvenS, LehmickeM, MartinettiR, FarhadiI, JakobM, ScherberichA and MartinI. (2010). Toward an intraoperative engineering of osteogenic and vasculogenic grafts from the stromal vascular fraction of human adipose tissue. Eur Cells Mater, 19:127–135.
6.
CheungWK, WorkingDM, GaluppoLD and LeachJK. (2010). Osteogenic comparison of expanded and uncultured adipose stromal cells. Cytotherapy, 12:554–562.
7.
JamesAW, ZaraJN, CorselliM, AskarinamA, ZhouAM, HourfarA, NguyenA, MegerdichianS, AsatrianG, et al. (2012). An abundant perivascular source of stem cells for bone tissue engineering. Stem Cells Transl Med, 1:673–684.
8.
Oedayrajsingh-VarmaMJ, van HamSM, KnippenbergM, HelderMN, Klein-NulendJ, SchoutenTE, MRittJPF and van MilligenFJ. (2006). Adipose tissue-derived mesenchymal stem cell yield and growth characteristics are affected by the tissue-harvesting procedure. Cytotherapy, 8:166–177.
9.
MeuryT, VerrierS and AliniM. (2006). Human endothelial cells inhibit BMSC differentiation into mature osteoblasts in vitro by interfering with osterix expression. J Cell Biochem, 98:992–1006.
10.
ClarkinCE, GaronnaE, Pitsillides and AA, Wheeler-JonesCPD. (2008). Heterotypic contact reveals a COX-2-mediated suppression of osteoblast differentiation by endothelial cells: a negative modulatory role for prostanoids in VEGF-mediated cell: cell communication?. Exp Cell Res, 314:3152–3161.
11.
RajashekharG, TraktuevDO, RoellWC, JohnstoneBH, Merfeld-ClaussS, Van NattaB, RosenED, MarchKL, and ClaussM. (2008). IFATS collection: adipose stromal cell differentiation is reduced by endothelial cell contact and paracrine communication: role of canonical Wnt signaling. Stem Cells, 26:2674–2681.
12.
XuJ, WangY, HsuCY, GaoY, MeyersCA, ChangL, ZhangL, BroderickK, DingC, et al. (2019). Human perivascular stem cell-derived extracellular vesicles mediate bone repair. Elife, 8:e48191.
13.
LeviB, NelsonER, LiS, JamesAW, HyunJS, MontoroDT, LeeM, GlotzbachJP, CommonsGW and LongakerMT. (2011). Dura mater stimulates human adipose-derived stromal cells to undergo bone formation in mouse calvarial defects. Stem Cells, 29:1241–1255.
14.
SchwaliePC, DongH, ZacharaM, RusseilJ, AlpernD, AkchicheN, CapraraC, SunW, SchlaudraffKU, et al. (2018). A stromal cell population that inhibits adipogenesis in mammalian fat depots. Nature, 559:103–108.
15.
CrisanM, YapS, CasteillaL, ChenCW, CorselliM, ParkTS, AndrioloG, SunB, ZhengB, et al. (2008). A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell, 3:301–313.
16.
IshimuraD, YamamotoN, TajimaK, OhnoA, YamamotoY, WashimiO and YamadaH. (2008). Differentiation of adipose-derived stromal vascular fraction culture cells into chondrocytes using the method of cell sorting with a mesenchymal stem cell marker. Tohoku J Exp Med, 216:149–156.
17.
ChungMT, LiuC, HyunJS, LoDD, MontoroDT, HasegawaM, LiS, SorkinM, RennertR, et al. (2013). CD90 (Thy-1)-positive selection enhances osteogenic capacity of human adipose-derived stromal cells. Tissue Eng Part A, 19:989–997.
18.
DaviesOG, CooperPR, SheltonRM, SmithAJ and SchevenBA. (2015). Isolation of adipose and bone marrow mesenchymal stem cells using CD29 and CD90 modifies their capacity for osteogenic and adipogenic differentiation. J Tissue Eng, 6:2041731415592356.
19.
JamesAW, ZaraJN, ZhangX, AskarinamA, GoyalR, ChiangM, YuanW, ChangL, CorselliM, et al. (2012). Perivascular stem cells: a prospectively purified mesenchymal stem cell population for bone tissue engineering. Stem Cells Transl Med, 1: 510–519.
20.
LiQ, QiLJ, GuoZK, LiH, ZuoHB and LiNN. (2013). CD73+ adipose-derived mesenchymal stem cells possess higher potential to differentiate into cardiomyocytes in vitro. J Mol Histol, 44:411–422.
21.
BaronR and KneisselM. (2013). WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med, 19:179–192.
22.
BalemansW, PatelN, EbelingM, Van HulE, WuytsW, LaczaC, DioszegiM, DikkersFG, HilderingP, et al. (2002). Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet, 39:91–97.
23.
LiX, OminskyMS, NiuQT, SunN, DaughertyB, D'AgostinD, KuraharaC, GaoY, CaoJ, et al. (2008). Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res, 23:860–869.
24.
OminskyMS, VlasserosF, JoletteJ, SmithSY, StouchB, DoellgastG, GongJ, GaoY, CaoJ, et al. (2010). Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res, 25:948–959.
25.
WitcherPC, MinerSE, HoranDJ, BullockWA, LimKE, KangKS, AdaniyaAL, RossRD, LootsGG and RoblingAG. (2018). Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition. JCI Insight, 3:e98673.
26.
CruciatCM and NiehrsC. (2013). Secreted and transmembrane Wnt inhibitors and activators. Cold Spring Harb Perspect Biol, 5:a015081.
27.
GongY, SleeRB, FukaiN, RawadiG, Roman-RomanS, ReginatoAM, WangH, CundyT, GlorieuxFH, et al. (2001). LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell, 107:513–523.
28.
MorvanF, BoulukosK, Clément-LacroixP, RomanSR, Suc-RoyerI, VayssièreB, AmmannP, MartinP, PinhoS, . (2006). Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res, 21:934–945.
29.
MorseA, ChengTL, SchindelerA, McDonaldMM, MohantyST, KneisselM, KramerI and LittleDG. (2018). Dkk1 KO mice treated with sclerostin antibody have additional increases in bone volume. Calcif Tissue Int, 103:298–310.
30.
McDonaldMM, MorseA, SchindelerA, MikulecK, PeacockL, ChengT, BobynJ, LeeL, BaldockPA, et al. (2018). Homozygous Dkk1 knockout mice exhibit high bone mass phenotype due to increased bone formation. Calcif Tissue Int, 102:105–116.
31.
GlantschnigH, ScottK, HamptonR, WeiN, McCrackenP, NantermetP, ZhaoJZ, VitelliS, HuangL, et al. (2011). A rate-limiting role for Dickkopf-1 in bone formation and the remediation of bone loss in mouse and primate models of postmenopausal osteoporosis by an experimental therapeutic antibody. J Pharmacol Exp Ther, 338:568–578.
32.
GlantschnigH, HamptonRA, LuP, ZhaoJZ, VitelliS, HuangL, HaytkoP, CusickT, IrelandC, et al. (2010). Generation and selection of novel fully human monoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bone mass in vivo. J Biol Chem, 285:40135–40147.
33.
LiX, GrisantiM, FanW, AsuncionFJ, TanH-L, DwyerD, HanC-Y, YuL, LeeJ, et al. (2011). Dickkopf-1 regulates bone formation in young growing rodents and upon traumatic injury. J Bone Miner Res, 26:2610–2621.
34.
JinH, WangB, LiJ, XieW, MaoQ, LiS, DongF, SunY, KeHZ, et al. (2015). Anti-DKK1 antibody promotes bone fracture healing through activation of β-catenin signaling. Bone, 71:63–75.
35.
KimJB, LeuchtP, LamK, LuppenC, Ten BergeD, NusseR and HelmsJA. (2007). Bone regeneration is regulated by Wnt signaling. J Bone Miner Res, 22:1913–1923.
36.
BajadaS, MarshallMJ, WrightKT, RichardsonJB and JohnsonWEB. (2009). Decreased osteogenesis, increased cell senescence and elevated Dickkopf-1 secretion in human fracture non union stromal cells. Bone, 45:726–735.
37.
ChenY, WhetstoneHC, LinAC, NadesanP, WeiQ, PoonR and AlmanBA. (2007). Beta-catenin signaling plays a disparate role in different phases of fracture repair: implications for therapy to improve bone healing. PLoS Med, 4:e249.
38.
KomatsuDE, MaryMN, SchroederRJ, RoblingAG, TurnerCH and WardenSJ. (2010). Modulation of Wnt signaling influences fracture repair. J Orthop Res, 28:928–936.
39.
ParkJR, JungJW, LeeYS and KangKS. (2008). The roles of Wnt antagonists Dkk1 and sFRP4 during adipogenesis of human adipose tissue-derived mesenchymal stem cells. Cell Prolif, 41:859–874.
40.
ChaeWJ and BothwellALM. (2019). Dickkopf1:an immunomodulatory ligand and Wnt antagonist in pathological inflammation. Differentiation, 108:33–39.
41.
DiM, WangL, LiM, ZhangY, LiuX, ZengR, WangH, ChenY, ChenW, ZhangY and ZhangM. (2017). Dickkopf1 destabilizes atherosclerotic plaques and promotes plaque formation by inducing apoptosis of endothelial cells through activation of ER stress. Cell Death Dis, 8:e2917.
42.
ChengSL, ShaoJS, BehrmannA, KrchmaK and TowlerDA. (2013). Dkk1 and Msx2-Wnt7b signaling reciprocally regulate the endothelial-mesenchymal transition in aortic endothelial cells. Arterioscler Thromb Vasc Biol, 33:1679–1689.
43.
UelandT, OtterdalK, LekvaT, HalvorsenB, GabrielsenA, SandbergWJ, Paulsson-BerneG, PedersenTM, FolkersenL, et al. (2009). Dickkopf-1 enhances inflammatory interaction between platelets and endothelial cells and shows increased expression in atherosclerosis. Arterioscler Thromb Vasc Biol, 9:1228–1234.
44.
GuoY, MishraA, HowlandE, ZhaoC, ShuklaD, WengT and LiuL. (2015). Platelet-derived Wnt antagonist Dickkopf-1 is implicated in ICAM-1/VCAM-1-mediated neutrophilic acute lung inflammation. Blood, 126:2220–2229.
45.
ChaeWJ, EhrlichAK, ChanPY, TeixeiraAM, HenegariuO, HaoL, ShinJH, ParkJH, TangWH, et al. (2016). The Wnt antagonist Dickkopf-promotes pathological type 2 cell-mediated inflammation. Immunity, 44:246–258.
46.
DiarraD, StolinaM, PolzerK, ZwerinaJ, OminskyMS, DwyerD, KorbA, SmolenJ, HoffmannM, et al. (2007). Dickkopf-1 is a master regulator of joint remodeling. Nat Med, 13:156–163.
47.
PinzoneJJ, HallBM, ThudiNK, VonauM, QiangYW, RosolTJ and ShaughnessyJD. (2009). The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood, 113:517–525.
48.
KamiyaN. (2012). The role of BMPs in bone anabolism and their potential targets SOST and DKK1. Curr Mol Pharmacol, 5:153–163.
49.
FlorioM, GunasekaranK, StolinaM, LiX, LiuL, TiptonB, Salimi-MoosaviH, AsuncionFJ, LiC, et al. (2016). A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair. Nat Commun, 7:11505.
50.
Van BezooijenRL, RoelenBAJ, VisserA, Van Der Wee-PalsL, De WiltE, KarperienM, HamersmaH, PapapoulosSE, Ten Dijke and CP, LöwikWGM. (2004). Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med, 199:805–814.
51.
WeivodaMM, YoussefSJ and OurslerMJ. (2017). Sclerostin expression and functions beyond the osteocyte. Bone, 96:45–50.
52.
AksuAE, RubinJP, DudasJR and MarraKG. (2008). Role of gender and anatomical region on induction of osteogenic differentiation of human adipose-derived stem cells. Ann Plast Surg, 60:306–322.
53.
ZhuM, KohanE, BradleyJ, HedrickM, BenhaimP and ZukP. (2009). The effect of age on osteogenic, adipogenic and proliferative potential of female adipose-derived stem cells. J Tissue Eng Regen Med, 3:290–301.
54.
BéréziatV, MazurierC, AuclairM, FerrandN, JollyS, MarieT, KobariL, ToillonI, DelhommeauF, et al. (2019). Systemic dysfunction of osteoblast differentiation in adipose-derived stem cells from patients with multiple myeloma. Cells, 8:441.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
